The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.
The firm said that it ended a distributor agreement that it had inked in 2013 with Fosun Long March Medical Science and Shanghai Xin Chang Medical Device.
The company, founded in May 2018 and headquartered in Guangzhou in southern China, has developed a CRISPR-based rapid diagnostics platform for pathogen detection.
The mass spec test is designed to measure blood-based proteins to predict type 2 diabetes patients' risk of developing diabetic kidney disease.
The tests are designed to monitor a patient's immune system for cancer responses rather than looking for tumor cells or specific biomarkers.
The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.
The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.
The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected.
Sysmex alleges multiple Beckman Coulter analyzers of infringing two patents covering technology for sensing blood or fluid samples.
Cytek said that the approval places the company on a path to offering a complete spectral flow cytometry solution — including instruments and reagents — to customers in China.